journal article·2022-02-23

Quantitative Detection of In Vivo Aggregation Degree for Enhanced M2 Macrophage MR Imaging

Lu-Jun Luo, Xiu-Mei Liu, Xiao Zhang, Jiao Liu, Yuanyuan Gao, Tong-Yi Sun, Li-Li Li

Nano Letters· Volume 22· Issue 4
Publisher page

Abstract

In situ self-assembly in vivo can be used in the enhanced diagnosis and therapy of major diseases such as cancer and bacterial infections on the basis of an assembly/aggregation-induced-retention (AIR) effect. However, the aggregation degree (αagg) is a significant parameter for determining the delivery efficiency to lesions in a complex physiological environment and a real-time quantitative calculation of the aggregation degree in vivo is still a great challenge. Here, we developed a magnetic resonance imaging (MRI) method for sensitive and quantitative calculation of αagg with a detection limit of 10–4 M and a bioactivated in vivo assembly (BIVA) magnetic resonance (MR) probe was optimized for enhanced T1-weighted MR imaging of M2 macrophages in tumors. Our MRI quantitative calculation method had a high fitting degree (R2 = 0.987) with the gold standard fluorescence (FL) method. On the basis of the BIVA mechanism of CD206 active targeting and cathepsin B specific tailoring to induce an in situ nanofiber assembly, our optimized BIVA probe exhibited a high intracellular aggregation degree of over 70% and a high in vivo αagg value of over 55%. Finally, the aggregation-enhanced T1 MR signal and the AIR effect both contributed to enhanced T1-weighted MR imaging of M2 macrophages in triple-negative breast cancer. We believe that our αagg real-time quantitative calculation method of MRI will help to further screen and optimize the in vivo enhanced imaging and treatment of the BIVA drug.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Supramolecular Self-Assembly in Materials

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST), No. 11 Beiyitiao, Zhongguancun, Beijing 100190, People’s Republic of China

School of Pharmacy, Weifang Medical University, Weifang 261053, Shandong, People’s Republic of China

Shandong Key Laboratory of Proteins and Peptides Pharmaceutical Engineering, Shandong Universities, Key Laboratory of Biopharmaceuticals, School of Life Science and Technology, Weifang Medical University, Weifang 261053, Shandong, People’s Republic of China

Funding

Ministry of Science and Technology of the People's Republic of China · National Natural Science Foundation of China · Chinese Academy of Sciences

References (36)

Show source-provided references
1. 10.1021/acsami.7b1905610.1021/acsami.7b19056 ↗
2. 10.1002/anie.20180249710.1002/anie.201802497 ↗
3. 10.2174/092986732466617092110315210.2174/0929867324666170921103152 ↗
4. 10.1002/adfm.20180449210.1002/adfm.201804492 ↗
5. 10.1016/j.watres.2005.10.03010.1016/j.watres.2005.10.030 ↗
6. 10.1016/j.biomaterials.2010.01.06510.1016/j.biomaterials.2010.01.065 ↗
7. 10.1021/jacs.8b1337610.1021/jacs.8b13376 ↗
8. 10.1039/C9CC01391A10.1039/C9CC01391A ↗
9. 10.1021/acs.chemrev.8b0036310.1021/acs.chemrev.8b00363 ↗
10. 10.1002/jmri.2372510.1002/jmri.23725 ↗
11. 10.1162/15353500275339567110.1162/153535002753395671 ↗
12. 10.1002/adfm.20140145110.1002/adfm.201401451 ↗
13. 10.1002/anie.20140013310.1002/anie.201400133 ↗
14. 10.1021/jacs.6b0971310.1021/jacs.6b09713 ↗
15. 10.1039/D0NR03218B10.1039/D0NR03218B ↗
16. 10.1021/acsami.6b0579510.1021/acsami.6b05795 ↗
17. 10.1021/bc500202b10.1021/bc500202b ↗
18. 10.1063/1.173014810.1063/1.1730148 ↗
19. 10.1016/0022-2852(61)90236-310.1016/0022-2852(61)90236-3 ↗
20. 10.1002/anie.20039031910.1002/anie.200390319 ↗
21. 10.1002/adma.20150198110.1002/adma.201501981 ↗
22. 10.1016/j.mattod.2020.11.00110.1016/j.mattod.2020.11.001 ↗
23. 10.1002/anie.20100230710.1002/anie.201002307 ↗
24. 10.1016/j.ccr.2017.09.00210.1016/j.ccr.2017.09.002 ↗
25. 10.1002/adma.20150343710.1002/adma.201503437 ↗
26. 10.1021/acs.nanolett.8b0228610.1021/acs.nanolett.8b02286 ↗
27. 10.1016/j.pnmrs.2006.03.00310.1016/j.pnmrs.2006.03.003 ↗
28. 10.1002/chem.20150224010.1002/chem.201502240 ↗
29. 10.1002/adma.20190491410.1002/adma.201904914 ↗
30. 10.1021/acs.analchem.6b0002310.1021/acs.analchem.6b00023 ↗
31. 10.1002/adma.20197032110.1002/adma.201970321 ↗
32. 10.1002/EXP.2021015310.1002/EXP.20210153 ↗
33. 10.1038/s41467-019-12848-510.1038/s41467-019-12848-5 ↗
34. 10.1002/adfm.20170714010.1002/adfm.201707140 ↗
35. 10.1038/s41551-017-005710.1038/s41551-017-0057 ↗
36. 10.1002/adma.20180633110.1002/adma.201806331 ↗